CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 265,537 enrolled
Drug / intervention
Neuromuscular blocking agentsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03585348
NCT03585348N/ACompleted

Importance of Understanding Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal Agents

Beth Israel Deaconess Medical Center·observational·Posted Jul 13, 2018·Updated Aug 25, 2021

In Brief

An observational study evaluating Neuromuscular blocking agents for Neuromuscular Blockade and 2 related conditions. Completed, enrolled 265,537 participants across 2 sites.

Detailed Summary

The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improvement projects since it is primarily individuals who determine the utilization of neuromuscular blocking drugs and reversal agents, not institutions. Therefore, the primary objective of this study is to determine the variability between individual anesthesia providers (attending physician, resident, nurse anesthetists) in the use of neuromuscular blocking drugs and reversal agents, using advanced statistical methods to adjust for differences in patient and procedure case mix. The investigators hypothesize that variance between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents differs depending on provider type.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 13, 2018
Enrollment StartJun 29, 2018
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.0 years ago

Interventions

Neuromuscular blocking agentsother

Neuromuscular blocking agent ED95 equivalent dose by provider